RXRX - Recursion Pharmaceuticals Inc.

AI-driven drug discovery platform combining AI, automation, and machine learning. Strong cash position of $665M+ providing runway into 2028. Encouraging safety and pharmacokinetic data from experimental drug programs. Analysts maintain bullish long-term outlooks on the AI-enabled drug discovery platform. Recent revenue missed expectations but investors focused on long-term platform potential.

Host highlights RXRX as one of the most advanced AI-driven drug discovery companies with a strong cash position of $753.9 million providing runway into early 2028, five clinical programs advancing, partnerships with major pharma companies generating over $500 million in payments, and an inflection point in clinical validation. Described as one of the most compelling AI biotech penny stocks.

Clinical-stage biotech using machine learning for drug discovery; first AI-driven clinical proof of concept with REC4881; nearly 15 discovery stage assets; $755M year-end cash providing runway through 2027; guiding 35% decline in operating expenses 2024-2026; Bank of America maintains hold with $7 price target implying ~50% upside; building a fully AI-native biotechnology enterprise

NVIDIA made a $50M strategic investment and owns ~7.7M shares. The company has a strong cash position of $785M extending runway into 2027, and its REC4881 drug candidate has potential for $1B in annual US sales. JP Morgan upgraded to overweight with an $11 price target. Priced at ~$4.66, it represents a high-risk, high-reward bet at the intersection of AI and healthcare.